Literature DB >> 1971043

Poliomyelitis outbreak in Israel in 1988: a report with two commentaries.

P E Slater1, W A Orenstein, A Morag, A Avni, R Handsher, M S Green, C Costin, A Yarrow, S Rishpon, O Havkin.   

Abstract

An outbreak of 15 cases of paralytic poliomyelitis caused by type 1 poliovirus between July and October, 1988, prompted mass vaccination of the whole Israeli population under the age of 40 years. The focus of the outbreak (12 cases) was the Hadera subdistrict, one of two subdistricts where enhanced inactivated poliovaccine (eIPV) had been the only poliovaccine used for infants since 1982. 9 of the 15 victims were 15 years or older, and 9 had previously been immunised with at least three doses of oral poliovaccine (OPV). The authors are divided in their interpretation of the findings. One group considered that the likely causative factors were the greater susceptibility of young adults previously vaccinated with OPV as well as transmission of wild poliovirus to susceptible people by children with low gut immunity against poliovirus after vaccination with eIPV; they concluded that a vaccination programme combining eIPV with OPV is the best option for Israel in future. The other group believed the causative factors were exposure to contaminated sewage or close social contact within the epidemic foci, the presence of an epidemic strain differing from the wild Mahoney and Sabin type 1 vaccine strains, and the lower seropositivity rates and geometric mean titres of neutralising antibodies to the epidemic than to vaccine strains; they believe that eIPV is the means to achieve effective control of poliomyelitis in Israel.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971043     DOI: 10.1016/0140-6736(90)92705-m

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  25 in total

1.  Detection of poliovirus circulation by environmental surveillance in the absence of clinical cases in Israel and the Palestinian authority.

Authors:  Y Manor; R Handsher; T Halmut; M Neuman; A Bobrov; H Rudich; A Vonsover; L Shulman; O Kew; E Mendelson
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

2.  A double-selective tissue culture system for isolation of wild-type poliovirus from sewage applied in a long-term environmental surveillance.

Authors:  Y Manor; R Handsher; T Halmut; M Neuman; B Abramovitz; A Mates; E Mendelson
Journal:  Appl Environ Microbiol       Date:  1999-04       Impact factor: 4.792

3.  Could an outbreak of poliomyelitis occur in the UK?

Authors:  S O Cameron; D Carrington; W Patterson
Journal:  BMJ       Date:  1992-01-04

Review 4.  Poliomyelitis: eradication in sight.

Authors:  J L Melnick
Journal:  Epidemiol Infect       Date:  1992-02       Impact factor: 2.451

Review 5.  Routine childhood immunisation: is it worth it?

Authors:  S P Conway; B Leese
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

6.  Antipoliomyelitis neutralizing antibodies in maternal and neonatal serum.

Authors:  M L Tanzi; P Colotto; M Vignali; P Affanni; U Bracchi; E Bellelli
Journal:  Eur J Epidemiol       Date:  1997-07       Impact factor: 8.082

7.  Polio vaccine: is it time for a change?

Authors:  A Finn; F Bell
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

8.  Professor Natan Goldblum and the combined vaccination program in Gaza.

Authors:  Ted Tulchinsky
Journal:  Am J Public Health       Date:  2011-05       Impact factor: 9.308

Review 9.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

10.  Comparing Israeli and Palestinian polio vaccination policies and the challenges of silent entry of wild poliovirus in 2013-14: a 'natural experiment'.

Authors:  Antoine Flahault; Walter Orenstein; Julie Garon; Olen Kew; Joan Bickford; Theodore Tulchinsky
Journal:  Int J Public Health       Date:  2015-11       Impact factor: 3.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.